China's BioDlink International HY revenue falls (September 29)

Overview

• China CDMO provider's half-year revenue fell to RMB 246 mln

• Company expanded CDMO operations and invested in R&D during the reporting period

• WuXi XDC completed acquisition, bringing new leadership and strategic direction

Outlook

• Company did not provide specific financial guidance in the interim report

Result Drivers

• CDMO EXPANSION - Co said accelerated expansion of CDMO operations contributed to results

• PRODUCT PRESSURE – Product revenue fell 89% yr/yr to RMB45 mln, mainly due to intensified market competition and volume-based procurement

• R&D RESOURCE REALLOCATION – R&D expenses fell 25% yr/yr to RMB27 mln as product pipelines were streamlined and resources shifted to CDMO development

Company press release: Full Story

Key Details

Analyst Coverage

• The one available analyst rating on the shares is "strong buy"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for BioDlink International Co Ltd is HK$4.40, about 17.3% above its September 28 closing price of HK$3.75

Reuters Recommended Reads

• Sept 28 - China's Fudan Microelectronics HY revenue, profit rise

• Sept 29 - Novo Nordisk to license GLP-1 drug from China's Hengrui in $2.6 billion deal

• Sept 28 - France's Inventiva H1 net loss narrows

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)